Clinical resource
Head and neck SCC hypopharynx, larynx, oropharynx, oral cavity adjuvant EBRT post-operative with or without chemotherapy (eviQ ID 3390)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for adjuvant radiotherapy after resection of squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx. It covers the risk features that prompt post-operative treatment, the added very-high-dose level for positive margins and extracapsular extension, and timing after surgery.
Why this is useful
Post-operative radiotherapy for resected oral cavity, oropharynx, larynx and hypopharynx cancers: dose levels, timing after surgery, when chemotherapy is added, and the shared organ table.
Reference details
- Title
- Head and neck SCC hypopharynx, larynx, oropharynx, oral cavity adjuvant EBRT post-operative with or without chemotherapy (eviQ ID 3390)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 3390
- Version
- v.4 — last reviewed 30 April 2026; review due 30 June 2030
- Year
- 2026
- DOI
- Pending verification
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Dose Constraints, Protocols
- Fractionation context
- 60 Gy / 30 fx with a 63 Gy high-risk level, or 62–66 Gy / 33 fx; SIB
- Last reviewed by DoseLab
- 2026-09-24